Cargando…
Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials
Advances, perspectives and innovation in drug delivery have increased in recent years; however, there is limited information available regarding the actual presence of surfactants, nanomedicines and nanocarriers in investigational medicinal products submitted as part of a request for authorization o...
Autores principales: | Dri, Diego Alejandro, Marianecci, Carlotta, Carafa, Maria, Gaucci, Elisa, Gramaglia, Donatella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999832/ https://www.ncbi.nlm.nih.gov/pubmed/33805639 http://dx.doi.org/10.3390/pharmaceutics13030381 |
Ejemplares similares
-
Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office
por: Dri, Diego Alejandro, et al.
Publicado: (2022) -
Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes
por: Dri, Diego Alejandro, et al.
Publicado: (2022) -
Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office
por: Dri, Diego Alejandro, et al.
Publicado: (2021) -
Regulatory Considerations on the use of Machine Learning based tools in Clinical Trials
por: Massella, Maurizio, et al.
Publicado: (2022) -
Smart Nanovesicles for Drug Targeting and Delivery
por: Marianecci, Carlotta, et al.
Publicado: (2019)